drugset / Trial / NCT00127569
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
Phase 2
Terminated
25 enrolled
French National Agency for Research on AIDS and Viral Hepatitis
Hoffmann-La Roche · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy. Efficacy is assessed by the complete response rate at day 60. The patients are followed until day 365.
Timeline
- Start
- 2003-05
- Primary completion
- —
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | — |